Operator
Good day, and thanks for standing by. Welcome to the Addex Therapeutics Half 12 months 2025 Monetary Outcomes, Company Replace Convention Name and Webcast. [Operator Instructions] Please observe that right this moment’s convention is being recorded.
I’d now like to show the convention over to your speaker, Tim Dyer, CEO. Please go forward, sir.
Timothy Dyer
Co-Founder, CEO & Director
Thanks. Hi there, everybody. I wish to thanks all for attending our half 12 months 2025 monetary outcomes convention name. I am right here with Mikhail Kalinichev, who will present an replace on our R&D packages. I draw your consideration to the press launch and the monetary statements issued yesterday, which can be found on the web site.
I additionally draw your consideration to our disclaimer. We might be guaranteeing forward-looking statements which might be primarily based on the data now we have right this moment.
I’ll begin this convention name by giving a fast overview of our latest actions and achievements earlier than reviewing our pipeline. I’ll then hand over to Misha, who will evaluate in additional element our GABAB PAM preclinical program for cough. I’ll then evaluate our monetary outcomes. Following that, we are going to open the decision for questions.
The primary half of 2025 has seen a number of vital achievements throughout our pipeline. We have made glorious progress in our GABAB PAM program with our companion, Indivior, efficiently finishing IND-enabling research with their selective drug candidate for substance use problems. As a reminder, beneath the phrases of the settlement, Addex is eligible for funds of as much as USD 330 million on profitable
